Stocks
ETFs
Options
Commodities
Crypto
Currency
Pro Newsletters
Research Tools
Daily Feeds
Calendars
Economic Indicators
Class Actions
Calculators
Education
About Us
Working with TipRanks
Follow Us
Cencora (COR)
NYSE:COR
Earnings Data
Report Date
Apr 30, 2025TBA Not Confirmed
Period Ending
2025 (Q2)Consensus EPS Forecast
4.06Last Year’s EPS
3.8Same Quarter Last Year
Moderate Buy
Based on 10 Analysts Ratings
---
Earnings Call Summary
Earnings Call Date:Feb 05, 2025
|% Change Since: -3.81%
|Next Earnings Date:Apr 30, 2025
Earnings Call Sentiment|Positive
The earnings call highlighted strong revenue and EPS growth, particularly in the U.S. healthcare solutions segment, and the strategic acquisition of RCA. Despite these positive developments, there were challenges such as decreased gross profit margin, subdued international operation results, and negative free cash flow. The overall sentiment is cautiously optimistic with strong underlying performance offset by some challenges.Company Guidance
During Cencora's Q1 fiscal year 2025 earnings call, the company reported a robust start with a 13% increase in revenue and a 14% rise in adjusted EPS. The U.S. healthcare solutions segment was highlighted as a significant contributor to this growth, with revenues up 14%, driven by strong prescription utilization trends and increased sales of GLP-1 products, which alone saw a 53% increase year-over-year. Operating income for the segment grew by 10%, despite headwinds from reduced COVID-19 vaccine sales. The company also raised its full-year adjusted diluted EPS guidance to a range of $15.25 to $15.55, reflecting continued momentum in its business segments and the impact of strategic acquisitions like RCA - Retina Consultants of America. Cencora expects consolidated revenue growth to be between 8% and 10%, with the U.S. segment leading at 9% to 11%, while international revenue growth is projected at 4% to 5% due to foreign currency impacts. The call emphasized strategic growth areas, including leadership in specialty, efficiency improvements, and a customer-centric approach to drive innovation and collaboration.Strong Revenue and EPS Growth
Cencora delivered a strong start to fiscal year 2025 with revenue growth of 13% and adjusted EPS growth of 14%.
U.S. Healthcare Solutions Segment Outperformance
The U.S. healthcare solutions segment revenue was $74 billion, up 14%, due to strong prescription utilization trends and increased sales of GLP-1 products.
Raising Full-Year Guidance
Cencora raised its full-year diluted EPS guidance to a range of $15.25 to $15.55 and consolidated revenue growth to 8% to 10%.
Acquisition of Retina Consultants of America (RCA)
Cencora completed the acquisition of RCA, a leading retina MSO, which is expected to contribute significantly to operating income growth.
---
COR Earnings History
The table shows recent earnings report dates and whether the forecast was beat or missed. See the change in forecast and EPS from the previous year.
Beat
Missed
---
COR Earnings-Related Price Changes
Report Date | Price 1 Day Before | Price 1 Day After | Percentage Change |
|---|---|---|---|
| Feb 05, 2025 | $251.00 | $252.71 | +0.68% |
| Nov 06, 2024 | $232.94 | $244.27 | +4.86% |
| Jul 31, 2024 | $229.49 | $236.30 | +2.97% |
| May 01, 2024 | $236.92 | $227.16 | -4.12% |
Earnings announcements can affect a stock’s price. This table shows the stock's price the day before and the day after recent earnings reports, including the percentage change.
---
FAQ
When does Cencora (COR) report earnings?
Cencora (COR) is schdueled to report earning on Apr 30, 2025, TBA Not Confirmed.
What is Cencora (COR) earnings time?
Cencora (COR) earnings time is at Apr 30, 2025, TBA Not Confirmed.
Where can I see when companies are reporting earnings?
You can see which companies are reporting today on our designated earnings calendar.
What companies are reporting earnings today?
You can see a list of the companies which are reporting today on TipRanks earnings calendar.
What is COR EPS forecast?
COR EPS forecast for the fiscal quarter 2025 (Q2) is 4.06.
---